European Court Invalidates Sandoz’s Patent for Generic Hypertension Drug

Pharmaceuticals manufacturer Sandoz has encountered a setback as a European appellate panel has ruled against the patent for its formulation of a generic drug designed to treat pulmonary hypertension. The decision was based on the finding that the ingredient aimed at enhancing the stability of the drug was considered obvious. For further details, the ruling can be reviewed here.